The FDA granted accelerated approval to Lunsumio VELO for adults with relapsed/refractory follicular lymphoma after two or ...
The U.S. Food and Drug Administration (FDA) approved six new therapies in December 2025 for blood cancers, prostate cancer, ...
A 29-year-old woman was referred to Tufts Medical Center for undifferentiated bilateral anterior and intermediate uveitis.The ...
Secura Bio, Inc. ( an integrated pharmaceutical company maximizing commercial outcomes for oncology medicines, today provided a corporate update, including an update on the encouraging enrollment ...
(Nasdaq: SNGX) (Soligenix or the Company), a late-stage biopharmaceutical company focused on developing and commercializing products to treat rare diseases where there is an unmet medical need, ...
Newser on MSN
Questions linger 250 years after Jane Austen's death
Tuesday marks 250 years since Jane Austen's birth, and despite much scrutiny, we're still in the dark about the novelist's cause of death. Austen died in her sister's arms in 1817 at 41 after nearly a ...
Study results support advancing SGX945 in this difficult-to-treat orphan disease Results suggest potential durability of response for maintenance therapy PRINCETON, N.J., Dec. 18, 2025 ...
Most people with lupus have it affect the skin. The types of rashes can be divided into two large groups. First, when lupus affects the skin with problems only seen in lupus, it’s called cutaneous ...
Cancer therapies can cause significant skin, scalp, and nail side effects in nearly two-thirds of patients, impacting comfort and confidence. Oncodermatology, a specialized field, aims to manage these ...
The subcutaneous formulation of the bispecific antibody reduces treatment time to 1 minute vs 2-4 hours with IV infusion.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback